Furthermore, we found that 6–8 out of 10 sgRNAs targeting Ankrd52 were significantly enriched in WT and immunotherapy tumors compared to T cell-depleted tumors (Fig. 2e, f), suggesting that inactivation of ANKRD52 conferred a selective advantage for tumor cells against PD-1 independent T cell-mediated immunity. The gene discussed is PDCD1; the disease is neoplasm.